Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17478877 | 0.95 | OPRK1 (0.50) | OPRK1ALDH1A1HCRTR1HCRTR2MAPK1 | |
| SCHEMBL17478934 | 0.85 | POLB (0.47) | ALDH1A1KDM4E | |
| SCHEMBL1645946 | 0.84 | HCRTR1 (0.48) | HCRTR1HCRTR2MAPK1SMN1; SMN2 | |
| SCHEMBL17478731 | 0.84 | HCRTR1 (0.54) | ALDH1A1HCRTR1HCRTR2MAPK1SMN1; SMN2 | |
| SCHEMBL19680534 | 0.84 | TP53 (0.44) | — | |
| SCHEMBL17478885 | 0.81 | CYP11B2 (0.45) | OPRK1ALDH1A1KDM4EHPGD | |
| SCHEMBL29574379 | 0.80 | OPRK1 (0.75) | OPRK1 | |
| SCHEMBL3719404 | 0.80 | OPRK1 (0.75) | OPRK1 | |
| SCHEMBL17478760 | 0.80 | CYP11B2 (0.49) | HPGD | |
| SCHEMBL17478690 | 0.80 | CYP11B2 (0.44) | ALDH1A1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | OPRK1 2806/4885ALDH1A1 3848/4885HCRTR1 3799/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | OPRK1 2806/4885ALDH1A1 3848/4885HCRTR1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.